Literature DB >> 31428810

[Importance of FDG-PET/computed tomography in colorectal cancer].

S Kleiner1, W Weber2.   

Abstract

BACKGROUND: Hybrid imaging FDG PET/CT (18F‑fluordeoxyglucose positron emission tomography/computed tomography) has gained increasing importance in oncology in recent years. DIAGNOSIS: A focal increase in FDG uptake in the gastrointestinal tract may be due to colorectal carcinoma. Such a finding requires further clarification. PRIMARY STAGING: Staging of the primary and locoregional lymph nodes remains a domain of established imaging modalities as FDG PET/CT does not provide a clear additional benefit. Liver metastases can be detected with high sensitivity by FDG PET/CT, but MRI is superior in small lesions. RADIATION THERAPY PLANNING: So far FDG PET/CT plays a subordinate role in the radiation therapy planning of rectal cancer. However, it can potentially contribute to the optimization of planning target volumes. THERAPY MONITORING: FDG PET/CT is suitable for monitoring therapy because morphological and metabolic changes of the tumor can be detected in early stages. This enables early detection of nonresponders after beginning neoadjuvant chemoradiation therapy of rectal cancer. FDG PET/CT can also be used for therapy control of liver metastases, especially after local therapeutic procedures. DETECTION OF RECURRENCE: With clinical suspicion of local recurrence and increased tumor markers, FDG PET/CT is a valuable tool as tumor recurrence can be detected with high sensitivity and specificity.

Entities:  

Keywords:  Colorectal neoplasms; Multimodal Imaging; Recurrence; Staging; Therapy monitoring

Mesh:

Substances:

Year:  2019        PMID: 31428810     DOI: 10.1007/s00117-019-00584-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  34 in total

1.  Radiologic measurement of tumor size in clinical trials: past, present, and future.

Authors:  S Saini
Journal:  AJR Am J Roentgenol       Date:  2001-02       Impact factor: 3.959

2.  PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.

Authors:  Ora Israel; Nikolay Yefremov; Rachel Bar-Shalom; Olga Kagana; Alex Frenkel; Zohar Keidar; Doron Fischer
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

3.  Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results.

Authors:  Ehab M Kamel; Miriam Thumshirn; Kaspar Truninger; Marc Schiesser; Michael Fried; Barbara Padberg; Didier Schneiter; Sandro J Stoeckli; Gustav K von Schulthess; Katrin D M Stumpe
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

4.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

5.  18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer.

Authors:  Shai Friedland; Roy Soetikno; Marie Carlisle; Alan Taur; Tonya Kaltenbach; George Segall
Journal:  Gastrointest Endosc       Date:  2005-03       Impact factor: 9.427

6.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.

Authors:  Karen Kinkel; Ying Lu; Marcus Both; Robert S Warren; Ruedi F Thoeni
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

7.  Recommendations on the use of 18F-FDG PET in oncology.

Authors:  James W Fletcher; Benjamin Djulbegovic; Heloisa P Soares; Barry A Siegel; Val J Lowe; Gary H Lyman; R Edward Coleman; Richard Wahl; John Christopher Paschold; Norbert Avril; Lawrence H Einhorn; W Warren Suh; David Samson; Dominique Delbeke; Mark Gorman; Anthony F Shields
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

8.  The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT.

Authors:  Einat Even-Sapir; Hedva Lerman; Mordechai Gutman; Gennady Lievshitz; Limor Zuriel; Aaron Polliack; Moshe Inbar; Ur Metser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-21       Impact factor: 9.236

9.  High and typical 18F-FDG bowel uptake in patients treated with metformin.

Authors:  Eric Gontier; Emmanuelle Fourme; Myriam Wartski; Cyrille Blondet; Gerald Bonardel; Elise Le Stanc; Marina Mantzarides; Herve Foehrenbach; Alain-Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-05       Impact factor: 9.236

10.  Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer.

Authors:  I Sobhani; E Tiret; R Lebtahi; T Aparicio; E Itti; F Montravers; C Vaylet; P Rougier; T André; J M Gornet; D Cherqui; C Delbaldo; Y Panis; J N Talbot; M Meignan; D Le Guludec
Journal:  Br J Cancer       Date:  2008-02-26       Impact factor: 7.640

View more
  1 in total

1.  Metabolic activity via 18F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer.

Authors:  Jinling Song; Zhongwu Li; Lujing Yang; Maomao Wei; Zhi Yang; Xuejuan Wang
Journal:  BMC Cancer       Date:  2022-07-22       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.